Pharmaceutical

BlueRock and bit.bio link to develop regulatory T cell-based therapies

BlueRock Therapeutics signed an agreement with bit.bio to discover and manufacture iPSC-derived regulatory T cells (Tregs) based therapies.

Aug 4, 2023 - 20:00
BlueRock and bit.bio link to develop regulatory T cell-based therapies
BlueRock Therapeutics signed an agreement with bit.bio to discover and manufacture iPSC-derived regulatory T cells (Tregs) based therapies.
Read the original article

Tags:

Previous Article

Bangladesh and the dengue vaccine question

Next Article

The next privacy battle will be fought over health data

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: Pharma hopes reformulated drugs will skirt Medicare negotiations; Biogen to acquire Reata for $7.3 billion

STAT+: Pharmalittle: Pharma hopes reformulated drugs wi...

Jul 28, 2023

MorphoSys gets grant for novel compounds for treating d...

Apr 11, 2024

Is there a path forward for PEPFAR?

Is there a path forward for PEPFAR?

Sep 12, 2023